Table 3.
Treatment and severities of COVID-19 patients.
| All (n = 267) | Re-positive classification | P value | ||
|---|---|---|---|---|
| No (n = 237) | Yes (n = 30) | |||
| Treatment | ||||
| Quinolone | 179 (67%) | 157 (66%) | 22 (73%) | 0.44 |
| Cephalosporins | 116 (43%) | 100 (42%) | 16 (53%) | 0.25 |
| Ribavirin | 232 (87%) | 206 (87%) | 26 (87%) | > 0.99 |
| Oseltamivir | 53 (20%) | 45 (19%) | 8 (27%) | 0.32 |
| Abidor | 91 (34%) | 85 (36%) | 6 (20%) | 0.08 |
| Lopinavir ritonavir tablets | 27 (10%) | 27 (11%) | 0 | 0.053 |
| Glucocorticoids | 150 (56%) | 132 (56%) | 18 (60%) | 0.65 |
| Intravenous immunoglobulin | 114 (43%) | 104 (44%) | 10 (33%) | 0.27 |
| Ventilation | 25 (9%) | 21 (9%) | 4 (13%) | 0.5 |
| Severity | ||||
| Mild | 0 | 0 | 0 | NA |
| General | 154 (58%) | 143 (60%) | 11 (37%) | 0.03 |
| Severe | 88 (33%) | 74 (31%) | 14 (47%) | |
| Critical | 25 (9%) | 20 (8%) | 5 (17%) | |
| ARDS | 94 (35%) | 79 (33%) | 15 (50%) | 0.07 |
| CURB-65 | 0 (0–1) | 0 (0–1) | 1 (0–1) | 0.003 |
| SOFA | 1 (0–2) | 1 (0–2) | 2 (1–3) | 0.17 |
| APACHE II | 3 (1–4) | 3 (1–4) | 4 (2–5) | 0.02 |
| Days from onset to hospitalization, days | 7 (5–10) | 7 (5–10) | 7 (2–12) | 0.582 |
| Duration of hospital stay, days | 27 (20–36) | 25 (19–34) | 36 (30–44) | < 0.001 |
| Hospitalization expenses, RMB | 25,118 (15,018–39,915) | 24,232 (14,771–39,196) | 30,596 (21,537–51,332) | 0.01 |
Bold font indicates P value < 0.05.